Indivior Drug Patent Portfolio
Indivior owns 4 orange book drugs protected by 31 US patents Given below is the list of Indivior's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11458091 | Compositions and methods for the treatment of opioid overdose | 10 Jul, 2038 | Active |
| US10646484 | Methods to treat opioid use disorder | 22 Jun, 2038 | Active |
| US11000520 | Buprenorphine dosing regimens | 06 Nov, 2035 | Active |
| US11839611 | Buprenorphine dosing regimens | 06 Nov, 2035 | Active |
| US8921387 | Injectable flowable composition comprising buprenorphine | 06 Jan, 2032 | Active |
| US8975270 | Injectable flowable composition comprising buprenorphine | 05 Sep, 2031 | Active |
| US10558394 | Injectable flowable composition comprising buprenorphine | 25 Jun, 2031 | Active |
| US10198218 | Injectable flowable composition comprising buprenorphine | 06 Jun, 2031 | Active |
| US10592168 | Injectable flowable composition comprising buprenorphine | 06 Jun, 2031 | Active |
| US9272044 | Injectable flowable composition buprenorphine | 06 Jun, 2031 | Active |
| US9498432 | Injectable flowable composition comprising buprenorphine | 06 Jun, 2031 | Active |
| US9782402 | Injectable composition comprising buprenorphine | 06 Jun, 2031 | Active |
| US9827241 | Injectable flowable composition comprising buprenorphine | 06 Jun, 2031 | Active |
| US8475832 | Sublingual and buccal film compositions | 26 Mar, 2030 | Active |
| US11135216 | Sublingual and buccal film compositions | 07 Aug, 2029 | Active |
| US9687454 | Sublingual and buccal film compositions | 07 Aug, 2029 | Active |
| US10010612 | Sustained delivery formulations of risperidone compounds | 13 Feb, 2028 | Active |
| US10376590 | Sustained delivery formulations of risperidone compound | 13 Feb, 2028 | Active |
| US11013809 | Sustained delivery formulations of risperidone compound | 13 Feb, 2028 | Active |
| US11712475 | Sustained delivery formulations of risperidone compound | 13 Feb, 2028 | Active |
| US9180197 | Sustained delivery formulations of risperidone compounds | 13 Feb, 2028 | Active |
| US9186413 | Sustained delivery formulations of risperidone compounds | 13 Feb, 2028 | Active |
| US11110093 | Sustained release small molecule drug formulation | 05 Nov, 2026 | Active |
| US10058554 | Sustained release small molecule drug formulation | 26 Sep, 2026 | Active |
| US9597402 | Sustained release small molecule drug formulation | 26 Sep, 2026 | Active |
| US10406160 | Sustained release small molecule drug formulation | 26 Jun, 2026 | Active |
| US8603514 | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions | 03 Apr, 2024 | Expired |
| US8017150 | Polyethylene oxide-based films and drug delivery systems made therefrom | 13 Feb, 2023 | Expired |
| US10285910 | Sublingual and buccal film compositions | 11 Oct, 2022 | Expired |
| US9855221 | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions | 14 Feb, 2022 | Expired |
| US9931305 | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions | 14 Feb, 2022 | Expired |
Latest Legal Activities on Indivior's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Indivior.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 May, 2024 | US9498432 |
| Recordation of Patent eGrant | 12 Dec, 2023 | US11839611 |
|
Recordation of Patent Grant Mailed
Critical
| 12 Dec, 2023 | US11839611 |
|
Email Notification
Critical
| 12 Dec, 2023 | US11839611 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 12 Dec, 2023 | US11839611 |
| Mail Patent eGrant Notification | 12 Dec, 2023 | US11839611 |
| Patent eGrant Notification | 12 Dec, 2023 | US11839611 |
|
Email Notification
Critical
| 23 Nov, 2023 | US11839611 |
|
Issue Notification Mailed
Critical
| 22 Nov, 2023 | US11839611 |
| Dispatch to FDC | 07 Nov, 2023 | US11839611 |
|
Application Is Considered Ready for Issue
Critical
| 07 Nov, 2023 | US11839611 |
|
Issue Fee Payment Received
Critical
| 31 Oct, 2023 | US11839611 |
|
Issue Fee Payment Verified
Critical
| 31 Oct, 2023 | US11839611 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 30 Oct, 2023 | US10646484 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 08 Sep, 2023 | US10592168 |
Indivior's Drug Patent Litigations
Indivior's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 20, 2014, against patent number US8475832. The petitioner BioDelivery Sciences International, Inc., challenged the validity of this patent, with RB Pharmaceuticals Limited as the respondent. Click below to track the latest information on how companies are challenging Indivior's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9687454 | November, 2018 |
FWD Entered
(02 Jun, 2020)
| Indivior UK Limited | Dr. Reddy’s Laboratories S.A. |
| US9687454 | November, 2018 |
Terminated-Denied
(03 Jun, 2019)
| Indivior UK Limited | Dr. Reddy's Laboratories S.A. |
| US8603514 | June, 2017 |
Terminated-Denied
(20 Oct, 2017)
| MonoSol Rx, LLC | Par Pharmaceutical, Inc. |
| US8603514 | June, 2017 |
Terminated-Denied
(20 Oct, 2017)
| MonoSol Rx, LLC | Dr. Reddy’s Laboratories, Inc. |
| US8603514 | November, 2016 |
Terminated-Settled
(06 Oct, 2017)
| MonoSol Rx, LLC et al. | Mylan Technologies, Inc. et al. |
| US8017150 | May, 2016 |
Terminated-Denied
(05 Dec, 2016)
| MonoSol Rx, LLC | Dr. Reddy’s Laboratories, Inc. |
| US8603514 | May, 2016 |
Terminated-Denied
(05 Dec, 2016)
| MonoSol Rx, LLC | Dr. Reddy's Laboratories, Inc. |
| US8475832 | May, 2016 |
Terminated-Denied
(02 Dec, 2016)
| Indivior UK Limited | Dr. Reddy’s Laboratories, Inc. |
| US8475832 | December, 2015 |
Terminated-Denied
(10 Jun, 2016)
| Indivior UK Limited | Teva Pharmaceuticals USA, Inc. |
| US8017150 | December, 2015 |
Terminated-Denied
(23 May, 2016)
| MONOSOL RX, LLC | Teva Parmaceuticals USA Inc. |
| US8603514 | December, 2015 |
Terminated-Denied
(23 May, 2016)
| MONOSOL RX LLC | Teva Pharmaceuticals USA Inc |
| US8475832 | January, 2014 |
FWD Entered
(30 Jun, 2015)
| RB Pharmaceuticals Limited | BioDelivery Sciences International, Inc. |
| US8475832 | June, 2014 |
Terminated-Denied
(19 Dec, 2014)
| RB Pharmaceuticals Limited | BioDelivery Sciences International, Inc. |
Indivior Drug Patents' Oppositions Filed in EPO
Indivior drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 11, 2012, by Lts Lohmann Therapie-Systeme Ag. This opposition was filed on patent number EP02801042A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP15828368A | Mar, 2021 | ELKINGTON AND FIFE LLP | Granted and Under Opposition |
| EP11728037A | Oct, 2018 | Teva Pharmaceutical Industries Ltd. | Opposition rejected |
| EP10740493A | Oct, 2016 | LTS LOHMANN Therapie-Systeme AG | Patent maintained as amended |
| EP08725543A | Oct, 2016 | Lecomte & Partners | Opposition rejected |
| EP11157819A | Jun, 2014 | Ahrens, Gabriele | Patent maintained as amended |
| EP11162857A | Apr, 2014 | Generics [UK] Limited | Granted and Under Opposition |
| EP02782151A | Jun, 2013 | Acino Pharma AG | Revoked |
| EP02782151A | Jun, 2013 | Germann, Sandra | Revoked |
| EP02801042A | Sep, 2012 | Ahrens, Gabriele | Patent maintained as amended |
| EP02801042A | Sep, 2012 | LTS LOHMANN Therapie-Systeme AG | Patent maintained as amended |
Indivior's Family Patents
Indivior Drug List
Given below is the complete list of Indivior's drugs and the patents protecting them.
1. Opvee
Opvee is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11458091 | Compositions and methods for the treatment of opioid overdose |
10 Jul, 2038
(13 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Opvee's drug page
2. Perseris Kit
Perseris Kit is protected by 10 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10010612 | Sustained delivery formulations of risperidone compounds |
13 Feb, 2028
(3 years from now)
| Active |
| US10376590 | Sustained delivery formulations of risperidone compound |
13 Feb, 2028
(3 years from now)
| Active |
| US11013809 | Sustained delivery formulations of risperidone compound |
13 Feb, 2028
(3 years from now)
| Active |
| US11712475 | Sustained delivery formulations of risperidone compound |
13 Feb, 2028
(3 years from now)
| Active |
| US9180197 | Sustained delivery formulations of risperidone compounds |
13 Feb, 2028
(3 years from now)
| Active |
| US9186413 | Sustained delivery formulations of risperidone compounds |
13 Feb, 2028
(3 years from now)
| Active |
| US11110093 | Sustained release small molecule drug formulation |
05 Nov, 2026
(1 year, 10 months from now)
| Active |
| US10058554 | Sustained release small molecule drug formulation |
26 Sep, 2026
(1 year, 8 months from now)
| Active |
| US9597402 | Sustained release small molecule drug formulation |
26 Sep, 2026
(1 year, 8 months from now)
| Active |
| US10406160 | Sustained release small molecule drug formulation |
26 Jun, 2026
(1 year, 5 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Perseris Kit's drug page
3. Sublocade
Sublocade is protected by 12 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10646484 | Methods to treat opioid use disorder |
22 Jun, 2038
(13 years from now)
| Active |
| US11000520 | Buprenorphine dosing regimens |
06 Nov, 2035
(10 years from now)
| Active |
| US11839611 | Buprenorphine dosing regimens |
06 Nov, 2035
(10 years from now)
| Active |
| US8921387 | Injectable flowable composition comprising buprenorphine |
06 Jan, 2032
(7 years from now)
| Active |
| US8975270 | Injectable flowable composition comprising buprenorphine |
05 Sep, 2031
(6 years from now)
| Active |
| US10558394 | Injectable flowable composition comprising buprenorphine |
25 Jun, 2031
(6 years from now)
| Active |
| US10198218 | Injectable flowable composition comprising buprenorphine |
06 Jun, 2031
(6 years from now)
| Active |
| US10592168 | Injectable flowable composition comprising buprenorphine |
06 Jun, 2031
(6 years from now)
| Active |
| US9272044 | Injectable flowable composition buprenorphine |
06 Jun, 2031
(6 years from now)
| Active |
| US9498432 | Injectable flowable composition comprising buprenorphine |
06 Jun, 2031
(6 years from now)
| Active |
| US9782402 | Injectable composition comprising buprenorphine |
06 Jun, 2031
(6 years from now)
| Active |
| US9827241 | Injectable flowable composition comprising buprenorphine |
06 Jun, 2031
(6 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sublocade's drug page
4. Suboxone
Suboxone is protected by 8 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8475832 | Sublingual and buccal film compositions |
26 Mar, 2030
(5 years from now)
| Active |
| US11135216 | Sublingual and buccal film compositions |
07 Aug, 2029
(4 years from now)
| Active |
| US9687454 | Sublingual and buccal film compositions |
07 Aug, 2029
(4 years from now)
| Active |
| US8603514 | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
03 Apr, 2024
(8 months ago)
| Expired |
| US8017150 | Polyethylene oxide-based films and drug delivery systems made therefrom |
13 Feb, 2023
(1 year, 10 months ago)
| Expired |
| US10285910 | Sublingual and buccal film compositions |
11 Oct, 2022
(2 years ago)
| Expired |
| US9855221 | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
14 Feb, 2022
(2 years ago)
| Expired |
| US9931305 | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
14 Feb, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Suboxone's drug page